Selectively inhibiting PDE4 not only blocks this interaction but also suppresses angiogenesis and enhances the efficacy of bevacizumab in an orthotopic glioma model, opening new directions for anti-angiogenic treatment in malignant gliomas (36). The gene discussed is PDE4A; the disease is glioma.